Ignite Creation Date:
2025-12-24 @ 8:03 PM
Ignite Modification Date:
2025-12-31 @ 12:21 AM
Study NCT ID:
NCT01288404
Status:
COMPLETED
Last Update Posted:
2011-02-02
First Post:
2011-02-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium
Sponsor:
Ramathibodi Hospital
Organization:
Study Overview
Official Title:
A Pilot Study of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium
Status:
COMPLETED
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Hypothesis: Subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, preventing or retarding the progression of recurrence.
Detailed Description:
1. Impending recurrent pterygium
2. Anti-VEGF therapy
* Bevacizumab
* Subconjunctival injection
* Suppress neovascularization
2. Anti-VEGF therapy
* Bevacizumab
* Subconjunctival injection
* Suppress neovascularization
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: